- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07653685
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
A Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Participants With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Médicament: TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection
- Médicament: TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ruihua Xu, Doctor
- Numéro de téléphone: 020-87343468
- E-mail: xurh@syscc.org.cn
Lieux d'étude
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chine, 100034
- Pas encore de recrutement
- Peking University First Hospital
-
Contact:
- Shikai Wu, Doctor
- Numéro de téléphone: 15810037307
- E-mail: Skywu4923@sina.com
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Chine, 400016
- Pas encore de recrutement
- The First Affiliated Hospital of Chongqing Medical University
-
Contact:
- Tao Zhang, Doctor
- Numéro de téléphone: 13708311156
- E-mail: tumorzzt@163.com
-
-
Gansu
-
Lanzhou, Gansu, Chine, 730050
- Pas encore de recrutement
- Gansu Provincial Tumor Hospital
-
Contact:
- Zhihu Li, Master
- Numéro de téléphone: 18993042850
- E-mail: 245698692@qq.com
-
-
Guangdong
-
Foshan, Guangdong, Chine, 528000
- Pas encore de recrutement
- The First People's Hospital of Foshan
-
Contact:
- Wei Wang, Doctor
- Numéro de téléphone: 18038863618
- E-mail: wangwei@fsyyy.com
-
Guangzhou, Guangdong, Chine, 510060
- Recrutement
- Sun Yat-sen University Cancer Center
-
Contact:
- Ruihua Xu, Doctor
- Numéro de téléphone: 020-87343468
- E-mail: xurh@syscc.org.cn
-
Guangzhou, Guangdong, Chine, 510000
- Pas encore de recrutement
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Contact:
- Yanhon Den, Doctor
- Numéro de téléphone: 13925106525
- E-mail: dengyanh@mail.sysu.edu.cn
-
-
Guangxi
-
Nanning, Guangxi, Chine, 530000
- Pas encore de recrutement
- Guangxi Zhuang Autonomous Region Cancer Hospital
-
Contact:
- Rong Liang, Doctor
- Numéro de téléphone: 18677070811
- E-mail: 53371159@qq.com
-
-
Guizhou
-
Zunyi, Guizhou, Chine, 563000
- Recrutement
- The Affiliated Hospital of Zunyi Medical University
-
Contact:
- Jiwei Wang, Doctor
- Numéro de téléphone: 18013964231
- E-mail: zmu_wangjw@163.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, Chine, 150000
- Pas encore de recrutement
- Harbin Medical University Cancer Hospital
-
Contact:
- Tongsen Zheng, Doctor
- Numéro de téléphone: 15134569619
- E-mail: zhengtongsen@126.com
-
Contact:
- Yuxian Bai, Doctor
- Numéro de téléphone: 13945095085
- E-mail: bai_yuxian@126.com
-
Qiqihar, Heilongjiang, Chine, 161005
- Pas encore de recrutement
- Qiqihar First Hospital
-
Contact:
- Xiyuan Sun, Doctor
- Numéro de téléphone: 13945258792
- E-mail: sunxiyuan2004@126.com
-
-
Henan
-
Zhengzhou, Henan, Chine, 450000
- Pas encore de recrutement
- Henan Cancer Hospital
-
Contact:
- Ying Liu, Doctor
- Numéro de téléphone: 13783604602
- E-mail: yaya7207@126.com
-
Zhengzhou, Henan, Chine, 450000
- Pas encore de recrutement
- The Third People's Hospital of Zhengzhou
-
Contact:
- HaiCun Wang, Master
- Numéro de téléphone: 13803833783
- E-mail: whc1975@126.com
-
Zhengzhou, Henan, Chine, 450000
- Pas encore de recrutement
- The first affiliated hospital of Zhengzhou university
-
Contact:
- Yongxu Jia, Doctor
- Numéro de téléphone: 15237128281
- E-mail: fccjiayx@zzu.edu.cn
-
-
Hubei
-
Jingzhou, Hubei, Chine, 434099
- Pas encore de recrutement
- Jingzhou First People's Hospital
-
Contact:
- Yan Hu, Master
- Numéro de téléphone: 18163137369
- E-mail: helensparkle@163.com
-
Wuhan, Hubei, Chine, 430022
- Pas encore de recrutement
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contact:
- Hongli Liu, Doctor
- Numéro de téléphone: 13995680822
- E-mail: hongliliu@hust.edu.cn
-
-
Hunan
-
Changsha, Hunan, Chine, 410013
- Recrutement
- Hunan Cancer Hospital
-
Contact:
- Yi He, Doctor
- Numéro de téléphone: 18692237222
- E-mail: heyi@hnca.org.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, Chine, 210008
- Recrutement
- Nanjing Drum Tower Hospital
-
Contact:
- Yudong Qiu, Doctor
- Numéro de téléphone: 13951806490
- E-mail: yudongqiu510@163.com
-
Nanjing, Jiangsu, Chine, 210009
- Recrutement
- Zhongda Hospital Southeast University
-
Contact:
- CaiLian Wang, Doctor
- Numéro de téléphone: 13851756378
- E-mail: wangcailian65@hotmail.com
-
Nanjing, Jiangsu, Chine, 210000
- Pas encore de recrutement
- Jiangsu Provincial Cancer Hospital
-
Contact:
- Yuanhua Liu, Doctor
- Numéro de téléphone: 13305180356
- E-mail: yuanhualiu02@hotmail.com
-
-
Jiangxi
-
Nanchang, Jiangxi, Chine, 330000
- Pas encore de recrutement
- Jiangxi Provincal People's Hospital
-
Contact:
- Weirong Yao, Doctor
- Numéro de téléphone: 13907002901
- E-mail: 13907002901@126.com
-
-
Jilin
-
Changchun, Jilin, Chine, 130021
- Pas encore de recrutement
- Jilin Cancer Hospital
-
Contact:
- Hongxia Cui, Master
- Numéro de téléphone: 13504436090
- E-mail: 2503074283@qq.com
-
Changchun, Jilin, Chine, 130021
- Pas encore de recrutement
- The first hospital of Jilin University
-
Contact:
- Tingting Liang, Doctor
- Numéro de téléphone: 15804303776
- E-mail: liangting2006@163.com
-
-
Liaoning
-
Shenyang, Liaoning, Chine, 110000
- Recrutement
- Liaoning Cancer Hospital & Institute
-
Contact:
- Jingdong Zhang, Doctor
- Numéro de téléphone: 18040007878
- E-mail: 13804027878@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Chine, 710000
- Pas encore de recrutement
- The First Affiliated Hospital of Xi'an Jiaotong University Medical College
-
Contact:
- Aili Suo, Doctor
- Numéro de téléphone: 18991232561
- E-mail: Ailisuo@mail.xjtu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200127
- Recrutement
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
-
Contact:
- XiuYing Xiao, Doctor
- Numéro de téléphone: 13564579313
- E-mail: xiaoxiuying2002@163.com
-
-
Shanxi
-
Xi’an, Shanxi, Chine, 710000
- Pas encore de recrutement
- The Second Affiliated Hospital of Air Force Medical University
-
Contact:
- Haichuan Su, Doctor
- Numéro de téléphone: 18629190366
- E-mail: cntdgcp@163.com
-
Xi’an, Shanxi, Chine, 710000
- Pas encore de recrutement
- The First Affiliated Hospital of Air Force Medical University
-
Contact:
- Yongzhan Nie, Doctor
- Numéro de téléphone: 15091520001
- E-mail: nieyongzhan@qq.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chine, 300202
- Recrutement
- Tianjin Medical University Cancer Institute & Hospital
-
Contact:
- Zhanyu Pan, Master
- Numéro de téléphone: 18622221256
- E-mail: tjpanzy@126.com
-
Tianjin, Tianjin Municipality, Chine, 300121
- Pas encore de recrutement
- Tianjin Union Medical Center
-
Contact:
- Mingqing Zhang, Doctor
- Numéro de téléphone: 15122875158
- E-mail: zmq1003@163.com
-
-
Xinjiang
-
Ürümqi, Xinjiang, Chine, 830054
- Pas encore de recrutement
- Xinjiang Medical University Affiliated Tumor Hospital
-
Contact:
- YanLi Qu, Master
- Numéro de téléphone: 18160627963
- E-mail: quyanli73@163.com
-
-
Zhejiang
-
Lishui, Zhejiang, Chine, 323000
- Recrutement
- Lishui Municipal Central Hospital
-
Contact:
- Yanru Xie, Master
- Numéro de téléphone: 13567615770
- E-mail: 43437677@qq.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Participants voluntarily participate in this study, sign the informed consent form, and have good compliance
- Age: 18-75 years (including the boundary when signing the informed consent form)
- Eastern Cooperative Oncology Group (ECOG) score: 0-1
- Expected survival of more than 3 months
- Unresectable locally advanced or metastatic colorectal cancer diagnosed by histopathology/cytology
- HER2-Abnormally Expressed tested
- Presence of at least one measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Participants should agree to use contraception during the study and for 6 months after the end
Exclusion Criteria:
- Participants with previously confirmed Microsatellite Instability Microsatellite Instability-High Deficient Mismatch Repair (MSI-H/dMMR)
- Presence of conditions affecting intravenous, venous blood sampling, or multiple factors affecting oral medications
- Active inflammatory bowel disease within 28 days prior to first dose
- Other malignancies within 5 years prior to the first dose or currently suffering from other malignancies
- Unresolved toxicity greater than CTCAE Grade 1 due to any prior therapy
- Major surgical treatment, significant traumatic injury within 28 days prior to the first dose or anticipation of major surgery during study treatment
- Had wounds or fractures that had not been healed for a long time
- Cerebrovascular accident, deep venous thrombosis and pulmonary embolism within 6 months prior to the first dose
- Patients with a history of psychotropic substance abuse who cannot quit or have mental disorders
- Participants with any severe and/or uncontrolled disease
- Known tumor-related carcinomatous meningitis with symptoms of brain metastases or symptom control for less than 4 weeks
- Patients with imaging suggestive of tumor invasion of major blood vessels or fatal massive hemorrhage due to tumor rupture or invasion of major blood vessels judged by the investigator to be very likely to occur during the study
- Failure to control serous effusions requiring repeated drainage
- Local radiotherapy or 4. Bone marrow irradiation > 30% for bone metastasis before the first medication
- Known tumor-related spinal cord compression, weight-bearing bone pathological fracture, extensive bone metastasis, or uncontrollable tumor bone metastasis-related pain
- Patients who have received chemotherapy, targeted therapy, immunotherapy or other systemic anti-tumor drug therapy before the first medication;
- Received Chinese patent medicine treatment with anti-tumor indications in the package insert of National Medical Products Administration (NMPA) approved drugs before study treatment
- History of live attenuated vaccination before the first dose or planned live attenuated vaccination during the study;
- Previous history of severe allergy of unknown origin
- According to the investigator's judgment, there are concomitant diseases that seriously endanger the participants' safety or affect the completion of the study, or the participant is considered unsuitable for other reasons
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: TQB2930 injection +chemotherapy + Bevacizumab injection
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. Bevacizumab blocks VEGF binding to receptors and inhibits tumor angiogenesis. |
|
Comparateur actif: TQB2930 injection +chemotherapy
|
TQB2930 enhances the binding to HER2 protein on the surface of tumor cells and increases HER2 internalization by simultaneously targeting ECD2 and ECD4, two non-overlapping epitopes of HER2 protein, which in turn more effectively down-regulates HER2 protein on the surface of tumor cells and dually blocks HER2 signaling. Oxaliplatin can block DNA replication and transcription and induce tumor cell apoptosis. Irinotecan hydrochloride injection inhibits topoisomerase-I via its active metabolite SN-38, prevents religation of DNA single-strand breaks, causes irreversible DNA double-strand damage and induces tumor cell apoptosis. Capecitabine inhibits thymidylate synthase (TS) and interferes with DNA synthesis. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Recommended Phase 2 Dose
Délai: Baseline up to 21 days
|
It refers to the safe and effective dose range that can be used for phase II study determined through phase I clinical trial. |
Baseline up to 21 days
|
|
Adverse event (AE)
Délai: From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
Incidence and severity of adverse events. |
From the participants signing of the informed consent form to 28 days after the last dose or the start of new anti-tumor therapy (whichever occurs first)
|
|
Objective Response Rate
Délai: Baseline up to 24 months
|
The proportion of participants achieving complete response and partial response among the total evaluable cases. |
Baseline up to 24 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Half-life
Délai: Baseline up to 24 months
|
The time it takes for the concentration of a drug in the body (usually the plasma concentration) to decrease to half of its initial value. |
Baseline up to 24 months
|
|
Plasma concentration-time profiles
Délai: Baseline up to 24 months
|
Total area covered under the curve plotted with time as X-axis and plasma concentration as Y-axis. |
Baseline up to 24 months
|
|
Apparent clearance
Délai: Baseline up to 24 months
|
The rate at which the drug is cleared from the body. |
Baseline up to 24 months
|
|
Apparent terminal volume of distribution
Délai: Baseline up to 24 months
|
Describe the drug distribution in the body. |
Baseline up to 24 months
|
|
Trough plasma concentration
Délai: Baseline up to 24 months
|
Minimum plasma drug concentration level at the end of the dosing interval (before the next dosing). |
Baseline up to 24 months
|
|
Disease Control Rate
Délai: Baseline up to 24 months
|
The percentage of participants with a complete response, partial response, or stable disease as determined by RECIST 1.1. |
Baseline up to 24 months
|
|
Duration Of Response
Délai: Baseline up to 24 months
|
The time from the first assessment of the tumor as a complete response or partial response to the first occurrence of disease progression or death from any cause. |
Baseline up to 24 months
|
|
Progression Free Survival
Délai: Baseline up to 24 months
|
Progression Free Survival (PFS) is defined as the length of time from the start of treatment until the disease progresses or the patient dies from any cause. |
Baseline up to 24 months
|
|
Overall Survival
Délai: Baseline up to 24 months
|
The time from the start of initial treatment to death from any cause. |
Baseline up to 24 months
|
|
Anti-Drug Antibodies (ADA) incidence
Délai: Baseline up to 24 months
|
Proportion of anti-drug antibody produced in the population of patients using the drug. |
Baseline up to 24 months
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies intestinales
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Tumeurs intestinales
- Maladies rectales
- Maladies du côlon
- Tumeurs colorectales
- Thérapeutique
- Voies d'administration du médicament
- Pharmacothérapie
- Injections
Autres numéros d'identification d'étude
- TQB2930-Ib/II-02
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .